MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases

Prostate

Volumn 74, Issue 1, 2014, Pages 103-111

  Flatley, Brian ^a,b   Wilmott, Karen G ^b   Malone, Peter ^b   Cramer, Rainer ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

microseminoprotein; biomarkers; MALDI MS; prostatic diseases; urine

Indexed keywords

BETA MICROSEMINOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; DIGITAL RECTAL EXAMINATION; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; SENSITIVITY AND SPECIFICITY; URINALYSIS;

Β-MICROSEMINOPROTEIN; BIOMARKERS; MALDI MS; PROSTATIC DISEASES; URINE;

AGED; AGED, 80 AND OVER; DIGITAL RECTAL EXAMINATION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MALE; MIDDLE AGED; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84890118862     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22736     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893-2917.
2. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC,. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151 (5): 1283-1290.
3. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K,. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60 (21): 5941-5945.
4. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA,. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44 (1): 8-15.
5. Karas M, Hillenkamp F,. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60 (20): 2299-2301.
6. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, Committee IG,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29 (9): 1228-1242.
7. Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI,. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: Proposal for a modified Gleason scoring system. J Urol 2009; 182 (4): 1364-1370.
8. Tiss A, Smith C, Camuzeaux S, Kabir M, Gayther S, Menon U, Waterfield M, Timms J, Jacobs I, Cramer R,. Serum peptide profiling using MALDI mass spectrometry: Avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. Proteomics 2007; 7: 77-89.
9. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M,. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77.
10. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ,. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997; 25 (17): 3389-3402.
11. M'Koma AE, Blum DL, Norris JL, Koyama T, Billheimer D, Motley S, Ghiassi M, Ferdowsi N, Bhowmick I, Chang SS, Fowke JH, Caprioli RM, Bhowmick NA,. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun 2007; 353 (3): 829-834.
12. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF III., Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004; 172 (4 Pt 1): 1302-1305.
13. Wright ME, Han DK, Aebersold R,. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol Cell Proteomics 2005; 4 (4): 545-554.
14. Okamoto A, Yamamoto H, Imai A, Hatakeyama S, Iwabuchi I, Yoneyama T, Hashimoto Y, Koie T, Kamimura N, Mori K, Yamaya K, Ohyama C,. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions. Oncol Rep 2009; 21 (1): 73-79.
15. Lilja H, Abrahamsson PA,. Three predominant proteins secreted by the human prostate gland. Prostate 1988; 12 (1): 29-38.
16. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM,. Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4 (127): 127rv3.
17. Ramirez ML, Nelson EC, Evans CP,. Beyond prostate-specific antigen: Alternate serum markers. Prostate Cancer Prostatic Dis 2008; 11 (3): 216-229.
18. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF, Thomas G, Hunter DJ, Dean M, Chanock SJ,. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 2009; 106 (19): 7933-7938.
19. Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman GJ, Evans DG, Blanco I, Mercer C, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Kirk J, Lilja H, Easton D, Cooper C, Eeles R, Neal DE, Committee ISS, Collaborators IS, Collaborators UG,. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS ONE 2010; 5 (10): e13363.
20. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF,. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40 (3): 316-321.
21. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ,. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40 (3): 310-315.
22. Teni TR, Sheth AR, Kamath MR, Sheth NA,. Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett 1988; 43 (1-2): 9-14.
23. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE,. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2009; 70 (3): 333-340.
24. Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JZJ, Beliveau R,. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: Implication in tumor metastasis. Clin Exp Metastasis 2005; 22 (5): 429-439.
25. Henriksen R, Lundwall A, Udby L, Fernlund P,. The expression of beta-microseminoprotein but not CRISP3 is reduced in ovarian. Anticancer Res 2012; 32 (9): 3993-3999.
26. Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D,. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58 (4): 475-481.
27. Yeager M, Deng Z, Boland J, Matthews C, Bacior J, Lonsberry V, Hutchinson A, Burdett LA, Qi L, Jacobs KB, Gonzalez-Bosquet J, Berndt SI, Hayes RB, Hoover RN, Thomas G, Hunter DJ, Dean M, Chanock SJ,. Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. Hum Genet 2009; 126 (6): 743-750.
28. Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, Fenemore J, Irvine A, Sereda K, Dulude H,. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer 2005; 4 (2): 91-99.
29. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M,. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the polycomb group protein EZH2. Oncogene 2007; 26 (31): 4590-4595.
30. Snel B, Lehmann G, Bork P, Huynen MA,. STRING: A web-server to retrieve and display the repeatedly occurring. Nucleic Acids Res 2000; 28 (18): 3442-3444.